Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

ByNicholas Jacobus

June 19th 2026

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A

ByNicholas Jacobus

June 19th 2026

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

ByNicholas Jacobus

June 19th 2026

Additive Manufacturing's Application in Pharma and Biotech

ByMike Hollan

June 19th 2026

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim,

Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink

ByNicholas Jacobus,Brian Hilberdink

June 19th 2026

Pharmaceutical Executive Digital Edition - March 2010

Articles in this issue

Related Content

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

Additive Manufacturing's Application in Pharma and Biotech

Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink

Trending on PharmExec

Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

Additive Manufacturing's Application in Pharma and Biotech

How is Boehringer Ingelheim's Deliberate GLP-1 Strategy Different From Competitors?

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A